

AD-A117 376

DEFENCE RESEARCH ESTABLISHMENT SUFFIELD RALSTON (ALBERTA)

F/6 6/5

DEVELOPMENT OF PLAQUE ASSAY SYSTEMS FOR POLIOVIRUS. (U)

APR 82 R E FULTON, K MUNROE

UNCLASSIFIED

DRES-MEMO-1067

NL

1-1  
1-2

1-3

1-4

1-5

1-6

1-7

1-8

1-9

1-10

1-11

1-12

1-13

1-14

1-15

1-16


1-17

1-18

1-19

1-20

END  
011  
8-H  
011



AD A117376

UNCLASSIFIED

(3)

DRES

SUFFIELD MEMORANDUM

NO. 1067

DEVELOPMENT OF PLAQUE ASSAY SYSTEMS  
FOR POLIOVIRUS (U)

by

R.E. Fulton and K. Munroe

ACN 16B10

DTIC  
SELECTED  
JUL 23 1982  
S D

A

April 1982

This document has been approved  
for public release and sale; its  
distribution is unlimited.



UNCLASSIFIED

DEFENCE RESEARCH ESTABLISHMENT SUFFIELD  
RALSTON ALBERTA

SUFFIELD MEMORANDUM NO. 1067

DEVELOPMENT OF PLAQUE ASSAY SYSTEMS FOR POLIOVIRUS (U)

by

R.E. Fulton and K. Munroe

ACN 16B10

April 1982

**WARNING**

The use of this information is permitted subject to recognition  
of proprietary and patent rights .

UNCLASSIFIED

UNCLASSIFIED

DEFENCE RESEARCH ESTABLISHMENT SUFFIELD  
RALSTON ALBERTA

SUFFIELD MEMORANDUM NO. 1067

DEVELOPMENT OF PLAQUE ASSAY SYSTEMS FOR POLIOVIRUS (U)

by

R.E. Fulton and K. Munroe

Abstract

During the summer months of 1978, Ms. Krista Munroe was employed as a summer research assistant in the Department of Preventive Medicine, DRES. Her project was to develop a plaque assay system for the quantitation of infectious poliovirus type 1. Two different plaque assay techniques were developed and compared. The results of this work are presented in this Suffield Memorandum.



Accession For	
NTIS GRAAI	<input type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
University of G	<input type="checkbox"/>
JUL 1978	<input type="checkbox"/>
By	
L. J. [Signature]	
Approved	
Date	
File No.	
A	

UNCLASSIFIED

UNCLASSIFIED

DEFENCE RESEARCH ESTABLISHMENT SUFFIELD  
RALSTON ALBERTA

SUFFIELD MEMORANDUM NO. 1067

DEVELOPMENT OF PLAQUE ASSAY SYSTEMS FOR POLIOVIRUS (U)

by

R.E. Fulton and K. Munroe

Introduction

The Defence Research Establishment Suffield (DRES) large volume air sampler (LVAS) (1) is efficient in the collection of bacteria from air (2). This equipment is presently being considered as a means of collecting viruses from air. To properly evaluate the efficiency of the LVAS for virus collection, the development of a simple, reliable and efficient virus assay technique is required. To date, the plaque assay offers the most economical and reliable method for quantitation of infectious virus.

The usefulness of a plaque assay for quantitation of airborne viruses is dependent upon the suitability of a particular host biological system for isolation of a specific virus. Since host cells vary in their susceptibility to viruses, optimal conditions for host-cell-virus interaction must be ascertained for each type of virus to be collected and assayed.

The vaccine strain of poliovirus type 1 (Sabin) was chosen as a suitable test virus for initial evaluation of the efficiency and sensitivity of the LVAS for collection of viruses. This virus was chosen because it grows well in cell culture, its quantitation by plaque assay has been previously documented (3,4,5), and it is a relatively safe virus with which to work.

This report describes and compares two plaque assay techniques:

1. a modification of the technique used by Dr. C.M. Johnson-Lussenburg, University of Ottawa (personal communication), and
2. a modification of techniques as described by Stott et al. (6) and Killington et al. (7).

Results of an evaluation of commercially available cell culture Petri dishes for their suitability for use in plaque assays is also presented.

UNCLASSIFIED

MATERIALS AND METHODSCell Cultures

A continuous line of human embryonic lung carcinoma cells (L 132), kindly supplied by the University of Ottawa, were grown as monolayers in Earle's Minimum Essential Medium (MEM) (Flow Laboratories, Mississauga, Ontario), containing 10% fetal calf serum (FCS) (v/v), penicillin (P)/gentamicin (G) (10,000 I.U. per mL/0.2 mg per mL), and glutamine (0.29 g per L). Cells were cultured in 250 mL plastic tissue culture flasks (Falcon, Fisher Scientific, Edmonton, Alberta). When monolayers were established growth medium was removed and the cells washed twice with phosphate buffered saline (PBS) (incomplete Dulbecco; Med-Ox Chemicals, Ottawa, Ontario). Cells were then trypsinized with trypsin-EDTA (GIBCO, Burlington, Ontario) and resuspended in MEM growth medium. Plastic Petri dishes (60 x 15 mm) were seeded with five mL of the cell suspension diluted to contain  $1.75 \times 10^5$  cells/mL. The cells were incubated overnight or until confluence in an atmosphere of 5% CO<sub>2</sub> and 55% relative humidity. Cell culture Petri dishes from three commercial sources were evaluated for their suitability for plaque assays. Linbro® multi-dish four well Disposo plates were obtained from ICN, Montreal, Quebec. Falcon® single well culture dishes were obtained from Fisher Scientific, Edmonton, Alberta. LUX Contur® single well dishes were purchased from Microbiological Associates, Walkersville, Maryland.

Virus

Virus seed stock was supplied by the University of Ottawa. This virus was initially described as poliovirus type 1 (Sabin) but was later

determined by virus neutralization to be a mixture of poliovirus types 1 and 3. This virus seed was passaged six times in L 132 cells, then harvested and held at -90°C until required. The passaged virus was titrated by dilution end-point and the titer calculated using the Kärber method (8). The titer, expressed as 50% tissue culture infective dose (TCID<sub>50</sub>), was 10<sup>-7</sup>/0.1 mL.

Plaque Assays

Method I

This method was modified from a procedure obtained from Dr. C.M. Johnson-Lussenburg, University of Ottawa (personal communication).

Growth medium was removed from culture dishes containing confluent monolayers of L 132 cells and the cell sheets were washed twice with PBS containing 0.2% (v/v) bovine serum albumin (BSA) (PBS-BSA). Virus dilutions were prepared on ice in PBS-BSA and cultures were inoculated in duplicate with 0.1 mL of each appropriate virus dilution. The virus was allowed to adsorb for one hour on a level surface at 37°C in a humidified atmosphere (55%) containing 5% CO<sub>2</sub>. The inoculum was respread every 30 minutes by gentle tipping of the culture dishes. Excess inoculum was removed and five mL of agar overlay was added to each dish. The agar overlay medium consisted of the following final concentration of ingredients: 2X MEM; 0.2% NaHCO<sub>3</sub>; 200 µg/mL diethylaminoethyl-dextran (DEAE-dextran) (Pharmacia, Dorval, Quebec); 50 µg/mL bromodeoxyuridine (BUDR); 100 I.U./mL P, 0.2 µg/mL G; 30 mM MgCl<sub>2</sub>; 0.29 g/L glutamine; 2.0% FCS; 0.6% Ionagar #2 (Oxoid, Med-Ox Chemicals, Ottawa, Ontario); and sterile distilled water. The agar overlay was allowed to solidify on a

level surface at room temperature, after which the cultures were incubated for 72 hours at 37°C in a humid environment flushed with 5% CO<sub>2</sub>. The following controls were included:

1. cultures mock infected and overlayed with agar medium,
2. cultures mock infected and overlayed with liquid medium containing all components of agar medium except agar,
3. cultures inoculated with lowest dilution of virus and overlayed with liquid medium containing all components of agar overlay except agar, and
4. cultures inoculated with lowest dilution of virus and overlayed with liquid medium consisting of MEM containing 2% FCS.

At the end of the incubation period, cultures were fixed by adding 5 mL of 4% formaldehyde in saline to the agar surface and incubating for one hour at room temperature. The agar layer was then removed and the cell sheets stained for 15 minutes with 1% aqueous crystal violet. Excess dye was washed off with tap water and the stained cell sheets allowed to air dry. Plaques were counted on the same day and the titer calculated.

Method II

This method was modified from procedures described by Stott et al. (6) and Killington et al. (7).

Growth medium was removed from confluent monolayers of L 132 cells and the cell sheets washed twice with PBS-BSA. Virus dilutions were prepared on ice in PBS-BSA and cultures were inoculated in duplicate with 0.1 mL of appropriate virus dilution. The virus inoculum was allowed to

adsorb on a level surface for 2.0 hours at 37°C in an atmosphere of 5% CO<sub>2</sub> and 55% relative humidity. The inoculum was respread every 30 minutes. Excess inoculum was removed and five mL of appropriate overlay medium (agar or liquid) was added. The agar overlay medium consisted of the following final concentration of ingredients: 2X MEM; 0.2% NaHCO<sub>3</sub>; 100 I.U./mL P; 2.0 µg/mL G; 30 mM MgCl<sub>2</sub>; 5.0% tryptose phosphate broth (Flow Laboratories, Mississauga, Ontario); 0.29 g/L glutamine; 0.6% purified agar (GIBCO, Burlington, Ontario), 2.0% heat inactivated FCS, and sterile distilled water. The agar was allowed to solidify at room temperature on a level surface. The cultures were then incubated at 37°C in an atmosphere of 5% CO<sub>2</sub> and 55% relative humidity. Controls, as described in Method I, were included in each assay. After 72 hours of incubation, one of each of the duplicate cultures was fixed and stained according to a procedure described by Holland *et al.* (9), while the remaining culture of each set was stained according to the University of Ottawa method described in Method I. The staining procedure of Holland *et al.* (9) was performed as follows. The agar overlay was removed from the culture dishes and the cell sheets were fixed and stained by adding 5 mL of fixative-dye solution (1% crystal violet in 20% ethanol) directly onto the agar surface. After two minutes, the excess dye was removed by washing in tap water and the cell sheets allowed to air dry. Plaques were counted on the same day.

#### RESULTS

Plaques appeared as clear circular areas in a purple-stained cell sheet. Using method I, two sizes of plaques were observed. One type was medium sized, approximately 3 - 4 mm in diameter, while the other type was tiny (pin point). The average titer of the virus stock, using this method, and counting both sizes of plaques, was 1.2 x 10<sup>8.5</sup> plaque forming units

(pfu)/mL. Method II gave rise to pinpoint plaques only. Using this latter method, the average titer of the virus stock was  $2.1 \times 10^{8.5}$  pfu/mL. Both staining methods were adequate and resulted in well stained cell sheets and plaques which were clearly visible.

Initially, no plaques were obtained using method I. Consequently, a number of media components were individually examined to determine whether any of them was responsible for cell toxicity or plaque inhibition. Experiments were performed in which varying concentrations of BUDR, DEAE-dextran and  $MgCl_2$ , respectively, were added to liquid overlay media of both inoculated and uninoculated cultures, or, were omitted completely. Neither BUDR nor  $MgCl_2$  caused any apparent inhibition of cell growth or virus replication in the range of concentrations examined, including concentrations the same as, and greater than, those used in the agar overlay medium. DEAE-dextran, however, was found to be toxic to L 132 cells in liquid media at concentrations ranging from as little as 25  $\mu$ g/mL (1/10th of that used in the actual plaque assay) to 1000  $\mu$ g/mL, and to inhibit poliovirus cytopathic effect in concentrations  $>100$   $\mu$ g/mL.

Four different types of agar were evaluated for their effects on plaque production. There was no difference in the quality or quantity of plaques obtained when purified agar (Oxoid, Med-Ox Chemicals, Ottawa, Ontario), agarose (Marine Colloids Division, FMC Corp, Rockland, Maryland), or ionagar #2 were incorporated in the overlay medium. However, when a factory prepared purified agar suspension (GIBCO, Burlington, Ontario) was used, plaques were obtained which were marginally larger than those obtained with the other agar types examined.

During the course of the development of plaque assay systems for

poliovirus, several different types of cell culture Petri dishes were evaluated for their suitability in the assay. Linbro® multi-dish culture dishes did not support formation of cell monolayers. Few cells attached to the dish surface with the result that most remained suspended in the medium. Falcon® dishes did support healthy monolayers; however, the seeded cells tended to accumulate around the edges of the dish resulting in uneven growth of monolayers and cell sheets which were heavily populated around the edges but sparse in the center. In addition, the virus inoculum tended to accumulate at the edges. LUX Contur® culture dishes were found to be the most suitable. Homogeneous monolayers were formed across the whole dish surface and fluid inocula remained evenly in contact with the total cell sheet.

DISCUSSION

Using Method I, two sizes of plaques (medium sized and tiny) were observed. Under normal conditions, plaques obtained from a virus preparation which contains only one virus serotype or strain should be equal in size. The fact that our virus stock was found to contain two virus serotypes (polio type 1 and 3), may account for our observation of two plaque sizes. Using Method II, only tiny plaques were observed. This observation could be accounted for if the media conditions of Method II were suitable for plaque production by only one of the two virus serotypes contained in the virus stock. A limited number of trials was conducted in which Method I was compared to Method II, using the same virus stock as source of inoculum and identical experimental conditions. When both medium and tiny sized plaques were counted in cultures prepared according to Method I, the number of plaques observed for a given dilution was approximately half of the number of tiny plaques observed for the same

dilution using Method II. The factors contributing to our observations of two plaque sizes and the discrepancies in plaque count are not clearly understood and further experiments using virus stock which is homogeneous for polio type 1, are required.

Both of the staining methods which were evaluated produced equally acceptable results. However, in the method as described by Holland *et al.* (9), fixation and staining are accomplished in one step. For this reason, we found this procedure to be more convenient and less time-consuming.

DEAE-dextran was found to be toxic to L 132 cells in liquid overlay at concentrations < 2  $\mu$ g/mL. DEAE-dextran is often added to agar overlay media to eliminate virus-inhibitory properties present in some agars. These inhibitors have been identified as polyanions, specifically, sulfated polysaccharides, and act by combining with virus particles, forming non-infectious virus-inhibitor complexes (10). DEAE-dextran, a polycation, acts by combining with the polyanion, thus neutralizing its inhibitory effect. Since, in liquid overlay media there are no polyanions to neutralize the effects of DEAE-dextran, the polycations are available to react with other charged substances, including host cells. In view of these findings, the observation in our experiments of gross cytotoxicity associated with the use of DEAE-dextran in liquid overlay, is not surprising.

In an evaluation of a number of commercially available culture dishes for their suitability for plaque assays, LUX Contur® plates were found to be superior. These dishes, unlike the others tested, are designed with curved edges to minimize the effects of meniscus tension at the fluid-plastic interface. Thus cells in liquid media do not tend to accumulate

UNCLASSIFIED

/9

the edges, but are distributed evenly over the whole surface of the

UNCLASSIFIED

UNCLASSIFIED

/10

SUMMARY

1. Two plaque assay systems (Methods I and II) have been developed for the quantitation of infectious poliovirus.
2. In order to evaluate the relative merits of the two methods, with respect to quality and quantity of plaque production, as well as efficiency of reagents, labor and time, more experimentation is indicated.
3. DEAE-dextran may be used in agar overlay media but should not be used in liquid overlay media.
4. LUX Contur® culture dishes are highly suitable for virus plaque assays.

UNCLASSIFIED

References

1. Hadley, D.J., D.E. Davids and L.A. White. 1972. Modification of a large-volume air sampler (cyclone scrubber). Suffield Technical Note No. 311. Unclassified.
2. White, L.A., D.J. Hadley, D.E. Davids and R. Naylor. 1975. Improved large-volume sampler for the collection of bacteria cells from aerosol. *Appl. Micro.* 29: 335-339.
3. Dulbecco, R. and M. Vogt. 1954. Plaque formation and isolation of pure lines with poliomyelitis virus. 1954. *J. Exp. Med.* 99: 167-182.
4. Takemoto, K. 1966. Plaque mutants of animal viruses. 1966. *Progr. Med. Virol.* 8: 314-348.
5. Agnese, G., T. Crovari and G. Giacomtti. 1970. The problems of standardization of attenuated poliovirus titration techniques. *Progr. Immunol. Biol. Standard.* 4: 636-642.
6. Stott, E.J. and G.F. Heath. 1970. Factors affecting the growth of rhinovirus 2 in suspension cultures of L 132 cells. *J. Gen. Virol.* 6: 15-24.
7. Killington, R.A., D. Lee, E.J. Stott and J.A. Osborne. 1974. Studies on lysosomes of L 132 cells infected with either rhinovirus type 2 or poliovirus type 1. *J. Gen. Virol.* 22: 303-307.
8. Kärber, G. 1931. Beitrag zur kollektiven behandlung pharmakologischer reihenversuche. *Arch. Exp. Pathol. Pharmakol.* 162: 480-483.

UNCLASSIFIED

/12

9. Holland, J. and L. McLaren. 1959. Improved method for staining cell monolayers for virus plaque counts. *J. Bact.* 78: 596-597.
10. Takemoto, K.K. and H. Leibhaber. 1961. Virus-polysaccharide interactions. I. An agar polysaccharide determining plaque morphology of EMC virus. *Virol.* 14: 456-462.

UNCLASSIFIED

## DOCUMENT CONTROL DATA - R &amp; D

(Security classification of title, body of abstract and indexing annotation must be entered when the overall document is classified)

1. ORIGINATING ACTIVITY DEFENCE RESEARCH ESTABLISHMENT SUFFIELD		2a. DOCUMENT SECURITY CLASSIFICATION UNCLASSIFIED
		2b. GROUP
3. DOCUMENT TITLE DEVELOPMENT OF PLAQUE ASSAY SYSTEMS FOR POLIOVIRUS (U)		
4. DESCRIPTIVE NOTES (Type of report and inclusive dates) Suffield Memorandum No. 1067		
5. AUTHOR(S) (Last name, first name, middle initial) Fulton, R.E. and Munroe, K.		
6. DOCUMENT DATE April 1982	7a. TOTAL NO. OF PAGES 14	7b. NO. OF REFS 10
8a. PROJECT OR GRANT NO. 16810	8b. ORIGINATOR'S DOCUMENT NUMBER(S) Suffield Memorandum No. 1067	
9b. CONTRACT NO.	9b. OTHER DOCUMENT NO.(S) (Any other numbers that may be assigned this document)	
10. DISTRIBUTION STATEMENT Unlimited		
11. SUPPLEMENTARY NOTES	12. SPONSORING ACTIVITY	
13. ABSTRACT  During the summer months of 1978, Ms. Krista Munroe was employed as a summer research assistant in the Department of Preventive Medicine, DRES. Her project was to develop a plaque assay system for the quantitation of infectious poliovirus type 1. Two different plaque assay techniques were developed and compared. The results of this work are presented in this Suffield Memorandum. (U)		

**UNCLASSIFIED**  
**This Sheet Security Classification**

**KEY WORDS**

Plaque assay

Poliiovirus

**INSTRUCTIONS**

1. **ORIGINATING ACTIVITY:** Enter the name and address of the organization issuing the document.
- 2a. **DOCUMENT SECURITY CLASSIFICATION:** Enter the overall security classification of the document including special warning terms whenever applicable.
- 2b. **GROUP:** Enter security reclassification group number. The three groups are defined in Appendix 'M' of the DMR Security Regulations.
3. **DOCUMENT TITLE:** Enter the complete document title in all capital letters. Titles in all cases should be unclassified. If a sufficiently descriptive title cannot be selected without classification, show title classification with the usual one-capital-letter abbreviation in parentheses immediately following the title.
4. **DESCRIPTIVE NOTES:** Enter the category of document, e.g. technical report, technical note or technical letter. If appropriate, enter the type of document, e.g. interim, progress, summary, annual or final. Give the inclusive dates when a specific reporting period is covered.
5. **AUTHOR(S):** Enter the name(s) of author(s) as shown on or in the document. Enter last name, first name, middle initial. If military, show rank. The name of the principal author is an absolute minimum requirement.
6. **DOCUMENT DATE:** Enter the date (month, year) of Establishment approval for publication of the document.
- 7a. **TOTAL NUMBER OF PAGES:** The total page count should follow normal pagination procedures, i.e., enter the number of pages containing information.
- 7b. **NUMBER OF REFERENCES:** Enter the total number of references cited in the document.
- 8a. **PROJECT OR GRANT NUMBER:** If appropriate, enter the applicable research and development project or grant number under which the document was written.
- 8b. **CONTACT NUMBER:** If appropriate, enter the applicable number under which the document was written.
- 9a. **ORIGINATOR'S DOCUMENT NUMBER(S):** Enter the official document number by which the document will be identified and controlled by the originating activity. This number must be unique to this document.
- 9b. **OTHER DOCUMENT NUMBER(S):** If the document has been assigned any other document numbers (either by the originator or by the sponsor), also enter this number(s).
10. **DISTRIBUTION STATEMENT:** Enter any limitations on further dissemination of the document, other than those imposed by security classification, using standard statements such as:
  - (1) "Qualified requesters may obtain copies of this document from their defence documentation center."
  - (2) "Announcement and dissemination of this document is not authorized without prior approval from originating activity."
11. **SUPPLEMENTARY NOTES:** Use for additional explanatory notes.
12. **SPONSORING ACTIVITY:** Enter the name of the departmental project office or laboratory sponsoring the research and development. Include address.
13. **ABSTRACT:** Enter an abstract giving a brief and factual summary of the document, even though it may also appear elsewhere in the body of the document itself. It is highly desirable that the abstract of classified documents be unclassified. Each paragraph of the abstract shall end with an indication of the security classification of the information in the paragraph (unless the document itself is unclassified) represented as (TS), (S), (C), (R), or (U).  

The length of the abstract should be limited to 20 single-spaced standard typewritten lines: 7½ inches long.
14. **KEY WORDS:** Key words are technically meaningful terms or short phrases that characterize a document and could be helpful in cataloging the document. Key words should be selected so that no security classification is required. Identifiers, such as equipment model designation, trade name, military project code name, geographic location, may be used as key words but will be followed by an indication of technical context.

